Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma
A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma.
Cholangiocarcinoma
DRUG: Oxaliplatin, capecitabine, gemcitabine, cetuximab|DRUG: Oxaliplatin, capecitabine, gemcitabine cetuximab
PFS, Time from treatment start to progression or death., 6 months after last patient included
Response rate., 6 months after last patient included|Survival, 6 months after last patient included|Toxicity, 28 days after last treatment of last patient
A phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine in combination with cetuximab in patient with non-resectable liver metastases from cholangiocarcinoma.